← Leaderboards
David M Engelthaler
University Of California, San Francisco
$4,210,794
Attributed
$7,638,376
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,382,200 · 3
FDA$256,176 · 2
By mechanism
R01$6,855,164 · 2
R21$527,036 · 1
U19$256,176 · 2
Top collaborators
- John Zapata Metcalfe10 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bridget Marie Barker$4,599,845
- Anita Sil$24,389,913
- John Zapata Metcalfe$8,956,853
- Charles Yen Chiu$12,010,203
- Satya Dandekar$23,346,836
Others in their field
Other Emerging Leaders on “Genomics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- Scott Topper · Broad Institute, Inc.$153,234,573
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,892,657
- Leonard Freedmand · Leidos Biomedical Research, Inc.$96,686,407
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Scott Andrew Sutherland · Vignet, Inc.$37,105,117
Research focus
GenomicsPublic HealthDetectionMonitorNext Generation SequencingPharmaceutical PreparationsRegimenPredispositionResistanceIneffective TherapiesCost EfficientMycobacterium TuberculosisDeep SequencingNonprofit OrganizationsDrug ResistanceCohortMolecularDrug Resistance In TuberculosisIndividualized MedicineClinical ManagementPyrazinamideInternationalResistance ProfileResolution
Grant awards (14)
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$413,869
R01 · FY2025 · AI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$290,717
R01 · FY2025 · AI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$708,266
R01 · FY2024 · AI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$745,941
R01 · FY2023 · AI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$736,217
R01 · FY2023 · AI
Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis$793,285
R01 · FY2021 · AI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$732,119
R01 · FY2021 · AI
Understanding the natural Coccidioides bioaerosol in time and space and its relationship to disease$287,269
R21 · FY2021 · AI · contact PI
Arizona Department of Health Services Laboratory - MICRO TGEN Track 4$128,088
U19 · FY2021 · FD · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$731,288
R01 · FY2020 · AI
Understanding the natural Coccidioides bioaerosol in time and space and its relationship to disease$239,767
R21 · FY2020 · AI · contact PI
Arizona Department of Health Services Laboratory - MICRO TGEN Track 4$128,088
U19 · FY2020 · FD · contact PI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$912,893
R01 · FY2019 · AI
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection$790,569
R01 · FY2018 · AI